Tezosentan in Patients With Pulmonary Arterial Hypertension

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01094067
• Date of registration: 25/03/2010
• Prospective Registration: Yes
• Primary sponsor: Idorsia Pharmaceuticals Ltd.
• Public title: Tezosentan in Patients With Pulmonary Arterial Hypertension
• Scientific title: Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.
• Date of first enrolment: September 1, 2010
• Target sample size: 2
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT01094067
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Investigator).
• Phase: Phase 2

Countries of recruitment

France, Japan, United States

Key inclusion & exclusion criteria

Inclusion Criteria :

1. Signed informed consent prior to initiation of any study-mandated procedure

2. Male and female patients 18 years of age or older

3. Patients with PAH according to one of the following subgroups of the Dana Point
Classification Group 1:

- Idiopathic, or

- Heritable, or

- Associated with connective tissue disease

4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of
study mandated procedures):

- Resting mean pulmonary arterial pressure (mPAP) = 25 mmHg and

- Resting mean pulmonary vascular resistance (PVR) = 240 dyn•s•cm 5 and

- Pulmonary capillary wedge pressure = 15 mmHg

5. Modified NYHA functional class II-III

6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used
for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days
prior to Visit 1.

Exclusion Criteria :

1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups
not covered by inclusion criterion No. 3

2. Patients with sitting SBP < 100 mmHg

3. Patients with sitting DBP < 60 mmHg

4. Patients with body weight < 50 kg (110 lbs)

5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or
alkaline phosphatase > 3 times upper limit)

6. Patients with clinically significant chronic renal insufficiency (serum creatinine
>2.5mg/dL / 221 µmol/L)

7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g.,
treprostinil, iloprost and beraprost) within 28 days of Visit 1

9. Patients who have received any investigational drugs within 28 days of Visit 1

10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit
1

11. Psychotic, addictive or other disorder limiting the ability to provide informed
consent or to comply with the study

12. Life expectancy less than 12 months

13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum
test at Screening and urine test on Visit 1 and 2) or females who are not using a
reliable method of birth control (failure rate less than 1% per year) during the study
and for at least one month after last administration of study drug

14. Known hypersensitivity to any of the excipients of the drug formulation.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Pulmonary Arterial Hypertension

Intervention(s)

Drug: ACT-050089

Other: Placebo

Primary Outcome(s)

Absolute change in supine SBP from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in mmHg [Time Frame: 30 days]

Secondary Outcome(s)

Absolute change in heart rate from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in bpm [Time Frame: 30 days]

Secondary ID(s)

AC-051-207

Source(s) of Monetary Support

Please refer to primary and secondary sponsors